Sophie Wang will speak at the AIPLA Advanced Chemical & Biotech Patent Institute on May 12, 2026, at 12:00 PM in San Francisco, where she will serve as a panelist on the session titled “Navigating the PTAB Split: ODP After Cellect, Allergan, Baurin, and Baumeister.” The session will examine the renewed prominence of Obviousness-Type Double Patenting (ODP) following the Federal Circuit’s decisions in In re Cellect. Building on subsequent clarifications in Allergan, the session will explore the current ODP framework, the PTAB’s recent, and conflicting, approaches in Baurin and Baumeister, and potential issues from the appeal of Baumeister pending before the Federal Circuit. The discussion will conclude with practitioner-focused insights, including strategic considerations for prosecuting related applications with staggered filing and issuance timelines, approaches for anticipating and responding to ODP rejections amid PTAB uncertainty, and the potential impact of forthcoming appellate guidance on patent portfolio management and validity assessments. learn more